Holding Eliquis Before Colonoscopy
For routine colonoscopy, hold apixaban (Eliquis) for 2 days (48 hours) before the procedure, with the last dose taken at least 48 hours prior. 1
Risk Stratification
First, determine if your colonoscopy is high-risk or low-risk for bleeding:
- High-risk procedures: Polypectomy, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), stricture dilation 1
- Low-risk procedures: Diagnostic colonoscopy with or without biopsies 1
Specific Recommendations by Procedure Type
For High-Risk Colonoscopy (e.g., with planned polypectomy)
Hold apixaban for at least 48 hours before the procedure 1. This means taking your last dose 2 days before your scheduled colonoscopy. The FDA label for Eliquis confirms this approach, recommending discontinuation at least 48 hours prior to elective surgery or invasive procedures with moderate or high bleeding risk 2.
The Asian Pacific guidelines provide more nuanced guidance based on renal function 3:
- Normal kidney function (CrCl >80 mL/min): Hold for 2 days
- Mild-moderate renal impairment (CrCl 50-80 mL/min): Hold for 2 days
- Moderate renal impairment (CrCl 30-50 mL/min): Hold for 2 days
- Severe renal impairment (CrCl 15-30 mL/min): Hold for 2 days
Note that apixaban is less affected by renal impairment than other DOACs (only ~25% renal elimination), so the holding period remains consistent at 2 days across all renal function levels 3.
For Low-Risk Diagnostic Colonoscopy
Simply omit the morning dose on the day of the procedure 1. You can continue your regular dosing schedule up until the morning of your colonoscopy.
Important Caveats
Renal Function Considerations
Unlike dabigatran (which requires 72 hours for patients with CrCl 30-50 mL/min), apixaban maintains the same 48-hour holding period regardless of kidney function 1. However, if you have rapidly deteriorating renal function, consult a hematologist before proceeding 1.
When to Resume Apixaban
Restart apixaban within 24-48 hours after the procedure, depending on bleeding risk and whether adequate hemostasis was achieved 1, 2. The FDA label states to restart "as soon as adequate hemostasis has been established" 2.
Bridging Therapy
Bridging anticoagulation with heparin during the 24-48 hours after stopping apixaban is NOT generally required 2. This is a key advantage of DOACs over warfarin—their rapid offset of action (approximately 24 hours) means bridging is unnecessary for most patients 3.
Recent Evidence on Uninterrupted Anticoagulation
A 2025 study found that uninterrupted anticoagulation may be safe for routine colonoscopy in the setting of a systematic protocol, with no difference in bleeding or thromboembolic events compared to interrupted anticoagulation 4. However, this approach is not yet reflected in current guidelines, and the standard recommendation remains to hold apixaban for 48 hours for high-risk procedures 1.
Common Pitfalls to Avoid
Don't confuse apixaban with dabigatran: Dabigatran requires longer holding periods (72 hours) in patients with renal impairment, but apixaban does not 1
Don't use vitamin K or fresh frozen plasma: These are ineffective for reversing DOACs like apixaban 3
Don't routinely check coagulation studies: Unlike warfarin, apixaban doesn't require INR monitoring, and standard coagulation tests don't reliably reflect apixaban levels 3
Don't hold longer than necessary: Holding apixaban for more than 48 hours unnecessarily increases thrombotic risk without additional bleeding benefit 1